Danish National Lymphoma Registry

Arboe, Bente; Josefsson, Pär; Jørgensen, Judit; Haaber, Jacob; Jensen, Paw; Poulsen, Christian Bjørn; Rønnov-Jessen, Dorthe; Pedersen, Robert Schou; Pedersen, Per Trøllund; Frederiksen, Mikael; Pedersen, Michael; Brown, Peter de Nully

doi:10.2147/clep.s99470

Cited by 53 publications

(39 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All data sources were linked using the unique patient-specific civil personal registration number. Clinical data were obtained from the population-based Danish National Lymphoma Registry (LYFO) 14 and supplemented by medical records.…”

Section: Methodsmentioning

confidence: 99%

Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort

et al. 2019

View full text Add to dashboard Cite

Myeloid and lymphoid malignancies are postulated to have distinct pathogenetic mechanisms. The recent observation that patients with a myeloproliferative neoplasm have an increased risk of developing lymphoproliferative malignancy has challenged this assumption. We collected a nationwide cohort of patients with both malignancies. Patients diagnosed in 1990-2015 were identified through the national Danish Pathology Registry. We identified 599 patients with myeloproliferative neoplasm and a concomitant or subsequent diagnosis of lymphoma. Histopathological review of the diagnostic samples from each patient led to a final cohort of 97 individuals with confirmed dual diagnoses of myeloproliferative neoplasm and lymphoma. The age range at diagnosis was 19-94 years (median: 71 years). To avoid the inclusion of cases of therapy-induced myeloproliferative neoplasm occurring in patients previously treated for lymphoma, only patients with myeloproliferative neoplasm diagnosed unequivocally before the development of lymphoma were included. The average time interval between the diagnoses of the two malignancies was 1.5 years. In the majority of patients (90%) both diagnoses were established within 5 years from each other. Among the lymphoma entities, the frequency of peripheral T-cell lymphomas was markedly increased. Interestingly, all but one of the T-cell lymphomas were of angioimmunoblastic type. These findings suggest that myeloproliferative neoplasm and lymphoproliferative malignancy developing in the same patient may have common pathogenetic events, possibly already at progenitor level. We believe that the molecular characterization of the newly developed biorepository will help to highlight the mechanisms driving the genesis and clonal evolution of these hematopoietic malignancies.

show abstract

Section: Methodsmentioning

confidence: 99%

Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Patients were identified using national and regional registers and databases. [20][21][22] The Danish cohort was extracted from the nationwide Danish Lymphoma Register (LYFO), which includes clinical and outcome data. In a recent quality assessment, LYFO was shown to have a coverage of 95% of all Danish patients with lymphoma.…”

Section: Study Population and Data Sourcesmentioning

confidence: 99%

Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study

Biccler

Glimelius

Eloranta

et al. 2019

JCO

View full text Add to dashboard Cite

PURPOSE Estimates of short- and long-term survival for young patients with classic Hodgkin lymphoma (cHL) are of considerable interest. We investigated cHL prognosis in the era of contemporary treatment at different milestones during the follow-up. PATIENTS AND METHODS On the basis of a Nordic cohort of 2,582 patients diagnosed at ages 18 to 49 years between 2000 and 2013, 5-year relapse risks and 5-year restricted losses in expectation of lifetime were estimated for all patients and for patients who achieved event-free survival (EFS) for 12 (EFS12), 24 (EFS24), 36 (EFS36) or 60 (EFS60) months. The median follow-up time was 9 years (range, 2.9 to 16.8 years). RESULTS The 5-year overall survival was 95% (95% CI, 94% to 96%). The 5-year risk of relapse was 13.4% (95% CI, 12.1% to 14.8%) overall but decreased to 4.2% (95% CI, 3.8% to 4.6%) given that patients reached EFS24. Relapse risk for patients treated with six to eight courses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) was comparable to that of patients treated with six to eight courses of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) despite more adverse risk criteria among patients treated with BEACOPP. Both from diagnosis and if EFS24 was reached, the losses in expectation of lifetime during the following 5 years were small (from diagnosis, 45 days [95% CI, 35 to 54 days] and for patients who reached EFS24, 13 days [95% CI, 7 to 20 days]). In stage-stratified analyses of 5-year restricted loss in expectation of lifetime, patients with stages I to IIA disease had no noteworthy excess risk of death after they reached EFS24, whereas risk remained measurable for patients with stages IIB to IV cHL. CONCLUSION Real-world data on young patients with cHL from the Nordic countries show excellent outcomes. The outlook is particularly favorable for patients who reach EFS24, which supports limited relapse-oriented clinical follow-up.

show abstract

“…The LYFO registry prospectively collects clinical and pathological data on all Danish lymphoma patients from diagnosis until death, thereby minimising selection bias (Arboe et al, 2016). The registry is routinely merged with the Danish Cancer Registry (DCR), which in turn is updated with information on all cancers in Denmark since 1942 (Gjerstorff, 2011).…”

Section: Study Populationmentioning

confidence: 99%

“…We performed a population-based retrospective study, based on information entered into the Danish Lymphoma Group Registry (LYFO) (El-Galaly et al, 2015;Arboe et al, 2016), including all patients diagnosed with DLBCL in the period 1983-2014. We performed a population-based retrospective study, based on information entered into the Danish Lymphoma Group Registry (LYFO) (El-Galaly et al, 2015;Arboe et al, 2016), including all patients diagnosed with DLBCL in the period 1983-2014.…”

mentioning

confidence: 99%

“…The aim of the present study was to characterise the occurrence and identify factors associated with relapse occurring 5 years or more after achieving first CR (CR1) for patients with DLBCL. We performed a population-based retrospective study, based on information entered into the Danish Lymphoma Group Registry (LYFO) (El-Galaly et al, 2015;Arboe et al, 2016), including all patients diagnosed with DLBCL in the period 1983-2014. More specifically, the present study aimed at identifying (i) the overall frequency of late relapse, (ii) clinical and paraclinical parameters influencing the risk of late relapse and (iii) the impact of introducing rituximab on the occurrence of late relapse.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Clinical and treatment‐related features determining the risk of late relapse in patients with diffuse large B‐cell lymphoma

2017

View full text Add to dashboard Cite

It is still unclear whether there are clinically exploitable differences in the biology and behaviour of early versus late relapses in diffuse large B-cell lymphoma (DLBCL). The present study aimed to analyse a large population-based DLBCL cohort in order to identify (i) the frequency of late relapses (LR), (ii) parameters influencing the risk of LR, and (iii) the impact of introducing rituximab on the occurrence of LR. The data of 7247 DLBCL patients was obtained from the Danish Lymphoma Group Registry. Patients with LR had a lower International Prognostic Index and better performance score than early relapse (ER) patients. The use of radiotherapy lowered only the rate of ER while the use of rituximab yielded a lower occurrence of both ER and LR (P < 0·0001 and P < 0·0001, respectively), possibly suggesting a longer-lasting biological effect. Additionally, we found a female overrepresentation among LR patients that had received a rituximab-containing first line treatment. It was found that patients with LR had a significantly better 5-year overall survival compared to ER patients. In conclusion, LR was more frequently associated with low-risk features than ER. Furthermore, we found that the use of modern immunochemotherapy regimens in DLBCL lowers the risk of both ER and LR.

show abstract

Danish National Lymphoma Registry

Cited by 53 publications

References 11 publications

Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort

Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort

Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study

Clinical and treatment‐related features determining the risk of late relapse in patients with diffuse large B‐cell lymphoma

Contact Info

Product

Resources

About